{"id":"NCT01292239","sponsor":"Janssen Pharmaceutical K.K.","briefTitle":"A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients","officialTitle":"A Phase III, Randomized, Double-blind, Placebo-controlled Trial in Japan to Investigate the Efficacy and Safety of TMC435 vs. Placebo as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Treatment-Naive, Genotype 1, Hepatitis C-infected Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2012-10","completion":"2012-10","firstPosted":"2011-02-09","resultsPosted":"2013-12-09","lastUpdate":"2014-01-17"},"enrollment":183,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"TMC435","otherNames":[]},{"type":"DRUG","name":"Peginterferon alfa-2a (pegIFN alfa-2a)","otherNames":["PEGASYS"]},{"type":"DRUG","name":"Ribavirin (RBV)","otherNames":["COPEGUS"]}],"arms":[{"label":"TMC435 100 mg 12 Wks + PR 24/48","type":"EXPERIMENTAL"},{"label":"PBO 12 Wks + PR 48","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of TMC435 compared with placebo in combination with peginterferon alfa-2a (pegIFN alfa-2a) and ribavirin in treatment-naive patients with chronic genotype 1 hepatitis C virus (HCV) infection in Japan.","primaryOutcome":{"measure":"The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12)","timeFrame":"EOT (up to Week 24 or 48) and 12 weeks after the EOT (up to Week 36 or 60)","effectByArm":[{"arm":"TMC435 100 mg 12 Wks + PR 24/48","deltaMin":88.6,"sd":null},{"arm":"PBO 12 Wks + PR 48","deltaMin":61.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":28,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":123},"commonTop":["White blood cell count decreased","Neutrophil count decreased","Pyrexia","Anaemia","Rash"]}}